Novartis AG Net Change in Short-term Investments 2012-2026 | NVS
Novartis AG annual/quarterly net change in short-term investments history and growth rate from 2012 to 2026. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
- Novartis AG net change in short-term investments for the quarter ending March 31, 2026 was $1.099B, a 39.42% decline year-over-year.
- Novartis AG net change in short-term investments for the twelve months ending March 31, 2026 was $6.458B, a 131.89% increase year-over-year.
- Novartis AG annual net change in short-term investments for 2025 was $1.781B, a 350.49% decline from 2024.
- Novartis AG annual net change in short-term investments for 2024 was $-0.711B, a 106.7% decline from 2023.
- Novartis AG annual net change in short-term investments for 2023 was $10.607B, a 127.52% increase from 2022.
|
Novartis AG Annual Net Change in Short-term Investments (Millions of US $) |
|
|---|---|
| 2025 | $1,781 |
| 2024 | $-711 |
| 2023 | $10,607 |
| 2022 | $4,662 |
| 2021 | $-14,105 |
| 2020 | $-1,408 |
| 2019 | $2,333 |
| 2018 | $-1,968 |
| 2017 | $-31 |
| 2016 | $92 |
| 2015 | $-333 |
| 2014 | $1,917 |
| 2013 | $-29 |
| 2012 | $-1,123 |
| 2011 | $1,595 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $293.951B | $54.532B |
| Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |